Alembic Pharmaceuticals Limited — Updates, 26-07-2025: Press Release

Alembic Pharmaceuticals has secured USFDA final approval for its Carbamazepine Extended-Release Tablets (100mg, 200mg, and 400mg). This approval allows the company to market the drug, indicated as an anticonvulsant and for treating trigeminal neuralgia. The approved product targets an estimated market size of US$ 71 million, translating to approximately ₹590 Cr. This is a significant development for Alembic's US generics business.